A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2006-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-005-0070-zPMID 16052341
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC).

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma

  2004cited by this paper
• SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial.

  2004cited by this paper
• Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

  2004influential reference
• ZD1839 Modulates Paclitaxel Response in Renal Cancer by Blocking Paclitaxel-Induced Activation of the Epidermal Growth Factor Receptor–Extracellular Signal-Regulated Kinase Pathway

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT).

  2004cited by this paper
• Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma.

  2004cited by this paper
• Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

  2004influential reference
• Results of a Phase 2 Trial with Valproic Acid Alone or in Combination with All-Trans-Retinoic Acid (ATRA) in 29 Patients with Myelodysplastic Syndromes.

  2004cited by this paper
• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

  2003influential reference
• Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma

  2003cited by this paper
• Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma

  2003cited by this paper
• Metastatic renal cell cancer treatments.

  2003cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003influential reference
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003influential reference
• Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil.

  2002cited by this paper
• Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities.

  2001cited by this paper
• IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

  2001cited by this paper
• Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.

  2000cited by this paper
• Chemotherapy for renal cell carcinoma.

  1999cited by this paper
• The epidermal growth factor receptor and its inhibition in cancer therapy.

  1999cited by this paper
• Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer.

  1999cited by this paper
• Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.

  1998cited by this paper
• Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

  1998cited by this paper
• Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma.

  1997cited by this paper
• Concomitant overexpression of the EGFR and erbB‐2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis

  1996cited by this paper
• Renal-cell carcinoma.

  1996cited by this paper
• Epidermal growth factor receptor content in human renal cell carcinomas

  1994cited by this paper
• The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma.

  1994cited by this paper
• Renal cell carcinoma.

  1956cited by this paper

• A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma.

  2022cites this paper
• Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma

  2021cites this paper
• Claspin overexpression is associated with high‐grade histology and poor prognosis in renal cell carcinoma

  2020cites this paper
• Cystic Kidney Diseases Associated with Increased Cancer Risk: Tuberous Sclerosis Complex, Von Hippel-Lindau, and Birt-Hogg-Dubé

  2018cites this paper
• Prognostic impact of epidermal growth factor receptor on clear cell renal cell carcinoma: Does it change with different expression patterns?

  2016cites this paper
• Nephroprotective effect of β-sitosterol on N-diethylnitrosamine initiated and ferric nitrilotriacetate promoted acute nephrotoxicity in Wistar rats

  2016cites this paper
• EGFR and HER2: Relevance in Renal Cell Carcinoma

  2015cites this paper
• Detection of predictive markers for therapeutic stratification of salivary glands tumors.

  2014cites this paper
• Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming?

  2013cites this paper
• Safety and feasibility of targeted agent combinations in solid tumours

  2013cites this paper
• Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma

  2013cites this paper
• EGFR expression is linked to osteopontin and Nf-κB signaling in clear cell renal cell carcinoma

  2012cites this paper
• 3 The VHL-HIF Signaling in Renal Cell Carcinoma : Promises and Pitfalls

  2012cites this paper
• Lapatinib and renal cell carcinoma

  2012cites this paper
• EGFR Proteinexpression und genetische Alterationen in Nierenzellkarzinomen

  2012cites this paper
• Epigenetic regulation in RCC: opportunities for therapeutic intervention?

  2012cites this paper
• The VHL-HIF Signaling in Renal Cell Carcinoma: Promises and Pitfalls

  2012cites this paper
• Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma

  2012cites this paper
• Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma

  2011cites this paper
• A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma

  2011cites this paper
• EGF receptor inhibitors

  2011cites this paper
• Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins.

  2010cites this paper
• Molecular basis for the treatment of renal cell carcinoma

  2010cites this paper
• „Targeted therapy“ bei metastasiertem Nierenzellkarzinom

  2010cites this paper
• Cancer-Associated Fibroblasts Derived from EGFR-TKI–Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs

  2010cites this paper
• Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.

  2010cites this paper
• Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib

  2010cites this paper
• Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma

  2010cites this paper
• "Targeted therapy" bei metastasiertem Nierenzellkarzinom

  2010cites this paper
• UPDATE ON VACCINE DEVELOPMENT FOR RENAL CELL CANCER.

  2010cites this paper
• Renal involvement in tuberous sclerosis complex and von Hippel–Lindau disease: shared disease mechanisms?

  2009cites this paper
• Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells

  2009influential citation
• Systemic therapy for advanced renal cell carcinoma

  2009cites this paper
• Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

  2009cites this paper
• Review: Systemic therapy for advanced renal cell carcinoma

  2009cites this paper
• Expression and prognostic value of LRIG1 and the EGF-receptor family in renal cell and prostate cancer

  2009cites this paper
• Small-molecule inhibitors of the human epidermal receptor family

  2009cites this paper
• Molecular targeting agents in renal cell carcinoma: present strategies and future perspectives.

  2008cites this paper
• Targeted therapy for advanced renal cell cancer: cytokines and beyond.

  2008cites this paper
• Genomics of renal cell cancer — Does it provide breakthrough?

  2008cites this paper
• Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.

  2008cites this paper
• Allelic imbalances of the egfr gene as key events in breast cancer progression--the concept of committed progenitor cells.

  2008cites this paper
• Interferon-&agr; in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial

  2008cites this paper
• ErbB and Nrg: Potential Molecular Targets for Vestibular Schwannoma Pharmacotherapy

  2008cites this paper
• [New drugs for metastatic kidney cancer].

  2008cites this paper
• High Incidence of Oral Dysesthesias on a Trial of Gefitinib, Paclitaxel, and Concurrent External Beam Radiation for Locally Advanced Head and Neck Cancers

  2008cites this paper
• Targeted therapies in the treatment of renal cell carcinoma.

  2008cites this paper
• Targeted Therapy in Renal Cell Carcinoma

  2008cites this paper
• Translating Biology to Clinical Practice: Evolving Strategies for the Treatment of Renal Cell Carcinoma

  2008cites this paper
• Neue Medikamente beim metastasierten Nierenzellkarzinom

  2008cites this paper
• EGFR and VEGFR2 protein expressions in bone metastases of clear cell renal cancer.

  2007cites this paper
• EGFR targeting of solid tumors.

  2007cites this paper
• Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.

  2007cites this paper
• Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments

  2007cites this paper
• Epithelial growth factor receptor (EGFR) pathway and renal cell carcinoma

  2007influential citation
• Phenotype/ Genotype of Malignant Tumors in Bone Metastasis

  2007cites this paper
• Pharmacokinetic and pharmacogenetic profiling in solid cancer patients

  2007cites this paper
• Mechanisms of egfr Gene Transcription Modulation: Relationship to Cancer Risk and Therapy Response

  2006cites this paper
• Kinase inhibitors in the treatment of renal cell carcinoma.

  2006cites this paper
• Vascular endothelial growth factor in renal cell carcinoma

  2006cites this paper
• Current status and perspective of antiangiogenic therapy for cancer: urinary cancer

  2006cites this paper
• [Systemic therapy of metastatic renal cell carcinoma].

  2006cites this paper
• Mechanisms of egfr GeneTranscription Modulation : Relationship to Cancer Risk andTherapy Response

  2006cites this paper
• Molecular biology of renal cell carcinoma

  2006cites this paper
• Systemische Therapie des metastasierten Nierenzellkarzinoms

  2006cites this paper
• Epidermal Growth Factor Receptor Inhibitors: A Moving Target?

  2005cites this paper
• Open Access Journal of Urology Dovepress Update on Vaccine Development for Renal Cell Cancer

  year unknowncites this paper